Gene therapy patients monitored for 15 years in safety check
NCT ID NCT02473757
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 28 times
Summary
This study does not provide any new treatment. It follows up to 1,000 adults who previously received CAR T-cell gene therapy for blood cancers like lymphoma, leukemia, or multiple myeloma. The goal is to monitor for long-term side effects, as required by regulators. Participants will have blood draws, annual checkups for 4 years, and yearly phone or email contact for up to 15 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.